Ameliorative effects of bevacizumab against sepsis-induced acute kidney injury: investigation of inflammatory responses, pyroptosis-related signalling and angiogenesis in a murine model of polymicrobial sepsis
- 27 May 2026
- journal article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Abstract
Sepsis is a clinical issue with a major impact on in-hospital patients, resulting in multiple organ damage and increased risk of death. Acute kidney injury (AKI) is the most common organ that is vulnerable to sepsis and may progress to renal failure if not treated. Bevacizumab is a biopharmaceutical agent that disrupts the angiogenesis signalling pathway by binding to vascular endothelial growth factor (VEGF) and preventing it from coupling with cognate receptors. The present study aimed to assess the renoprotective potential of bevacizumab against sepsis-induced renal injury. Four cohorts (6 mice per group) were randomly allocated and included a sham cohort, which was exposed to a midline incision only; the cecal ligation and puncture (CLP) cohort underwent CLP; the vehicle cohort was pretreated with normal saline 1 h prior to the CLP; and the bevacizumab cohort was treated with 0.1 mg/kg bevacizumab 1 h before the CLP. After 24 h, the mice were euthanised, and the blood and kidneys were collected. The results revealed that the levels of urea, creatinine, TNF-α, IL-6, caspase 11, ICAM-1, VEGF and angiopoietin-2 were greater in septic mice than in sham mice. These levels were decreased in septic mice pretreated with bevacizumab. Histological assessment of renal tissues revealed that the kidneys of septic mice were injured, influencing 90% of the renal tubules. Pretreatment with bevacizumab mitigated renal tissue damage. This study demonstrated that bevacizumab has promising renoprotective effects against sepsis-induced renal injury via modulation of inflammatory responses, angiogenesis and pyroptosis-associated signalling.Keywords
This publication has 49 references indexed in Scilit:
- Bevacizumab alleviates kidney damage by modulating inflammation, necroptosis and apoptosis: a preclinical study of renal ischaemia/reperfusion injury in ratsJournal of Molecular Histology, 2025
- JAK1/JAK2 inhibitor baricitinib ameliorates sepsis-induced acute kidney injury in ratsEuropean Journal of Pharmacology, 2025
- Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectivesSignal Transduction and Targeted Therapy, 2025
- Morin attenuates sepsis-induced acute kidney injury by regulating inflammatory responses, oxidative stress and tubular regeneration (morin and sepsis-induced acute kidney injury)Environmental Toxicology and Pharmacology, 2024
- Kaempferol improves acute kidney injury via inhibition of macrophage infiltration in septic miceBioscience Reports, 2023
- Knockout of Erbin promotes pyroptosis via regulating NLRP3/caspase-1/Gasdermin D pathway in sepsis-induced acute kidney injuryClinical and Experimental Nephrology, 2023
- ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesisJournal of Leukocyte Biology, 2020
- Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease StudyThe Lancet, 2020
- Effect of bevacizumab on acetic acid–induced ulcerative colitis in ratsJournal of Surgical Research, 2017
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004